Skip to main content
Fig. 2 | BMC Psychiatry

Fig. 2

From: Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder

Fig. 2

Pharmacokinetics of tipepidine in TS-141 and Asverin group according to subjects. Each single line shows the plasma concentration of tipepidine after the administration of TS-141 30 mg (a) or Asverin 40 mg (b) by each subject. The correlation of tipepidine Cmax (ng/mL) and AUC0-∞ (ng⋅h/mL) in TS-141 30 mg (c) and Asverin 40 mg (d) was determined using the natural logarithm

Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us